

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format no later than three weeks prior to your defence.

Basic information

Name: Gitte Vrelits Sørensen Email: gitte@clin.au.dk Phone: +45 20438085

Department of: Clinical Medicine

Main supervisor: Henrik Hasle

Title of dissertation: Late effects in survivors of childhood acute lymphoblastic leukemia

Date for defence: 15-10-2021 at (time of day): 14.00 Place: Auditorium J116-113 (entrance J, krydspunkt 110 (level 1) Aarhus University Hospital, Palle Juul-Jensen Boulevard 165, 8200 Aarhus N

Press release (Danish)

Senfølger efter akut lymfoblastær leukæmi i barndommen.

Et nyt ph.d.-projekt fra Aarhus Universitet har undersøgt senfølger blandt overlevende efter akut lymfoblastær leukæmi (ALL) i barndommen med fokus på hospitaliseringer for somatiske sygdomme samt dødeligheden. Projektet er gennemført af Gitte Vrelits Sørensen, der forsvare det d. 15./10.-2021.

Fem-årsoverlevelsen for børn diagnosticeret med ALL er steget markant fra 10% i 1960erne til mere end 90% i dag. Helbredelsen har dog en pris, og følgerne af ALL og den intensive behandling kan persistere eller vise sig mange år efter endt behandling. Børn helbredt for ALL har potentielt mange leveår tilbage, hvilket understreger vigtigheden af mere viden og behovet for bedre karakteristik af senfølger hos børn med ALL. Studierne i ph.d.-projektet er alle populations-baserede og bygger på data fra unikke nordiske registre.

Forsvaret af ph.d.-projektet er offentligt og finder sted den 15/10-2021 kl. 14 i Auditorium J116-113 (indgang J, krydspunkt 110 (niveau 1) Aarhus Universitets Hospital, Palle Juul-Jensen Boulevard 165, 8200 Aarhus N. Titlen på projektet er "Late Effects in Survivors of Childhood Acute Lymphoblastic Leukemia". Yderligere oplysninger: Ph.d.-studerende Gitte Vrelits Sørensen, e-mail: gitte@clin.au.dk, tlf. +45 2043 8085.

Bedømmelsesudvalg:

Mette Nørgaard, MD, PhD, Professor (chair and moderator of the defense)
Department of Clinical Epidemiology, Aarhus University Hospital, Denmark

Riitta Niinimäki, MD, PhD, Associate Professor
Department of Pediatric Hematology and Oncology, Oulu University Hospital, Finland

Kevin Oeffinger, MD, Professor
Duke Cancer Institute, Duke University, North Carolina, USA

Press release (English)

Late effects of childhood acute lymphoblastic leukemia

In a new Ph.D. project from Aarhus University late effects of childhood acute lymphoblastic leukemia (ALL) have been investigated with a focus on hospital-based morbidity and late mortality. The project was carried out by Gitte Vrelits Sørensen, who is defending her dissertation on 15/10/2021..

Five-year survival rates for patients with childhood ALL have increased impressively from 10% in the 1960s to above 90% today. However, the advances in survival have come at a price, and adverse effects from ALL and the cytotoxic treatment may persist or become evident many years after cure from cancer. The potential long life remaining in these children underscores the need for more knowledge and better characterization of long-term effects of childhood ALL. The studies included in the Ph.D.-project are all population-based and use data from unique Nordic registries.

The defence is public and takes place on Friday, October 15, 2021 at 14:00 in Auditorium J116-113 (entrance J, level 1), Aarhus University Hospital, Palle Juul-Jensen Boulevard 165, 8200 Aarhus N. The title of the project is "Late effects in survivors of childhood acute lymphoblastic leukemia". For more information, please contact PhD student Gitte Vrelits Sørensen, email: gitte@clin.au.dk, Phone +45 2043 8085.

Assessment committee:

Mette Nørgaard, MD, PhD, Professor (chair and moderator of the defense)
Department of Clinical Epidemiology, Aarhus University Hospital, Denmark

Riitta Niinimäki, MD, PhD, Associate Professor
Department of Pediatric Hematology and Oncology, Oulu University Hospital, Finland

Kevin Oeffinger, MD, Professor
Duke Cancer Institute, Duke University, North Carolina, USA

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.